According to a recently published report by Research Nester on “Global Meningococcal Vaccine Market: Global Demand Analysis & Opportunity Outlook 2019-2027” delivers detailed overview of the global meningococcal vaccination market in terms of market segmentation by composition, by brand, by end user and by regions.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The meningococcal vaccine market is segmented by composition (mono vaccines and combination vaccines); by brand (menactra, menveo, neisvac-c, nimentrix and others); by end users (children, preteens and teens & adults) and by regions.

The occurrence of meningococcal disease relies on several factors inclusive of age, geographical location, environmental fettle, and immunity. Such a wide range of factors responsible for the diseases also increases its rate of incidence, and this gives an impetus to the growth of the global market for meningococcal vaccines. The rising incidence of the disease is rebutted by the awareness campaigns to inform and educate people about the ills of meningococcal disease and ways to prevent and treat it. This has also created growth spaces for the pharmaceutical companies manufacturing vaccines and drugs for the treatment of meningococcal. The efforts of international bodies towards building a strong healthcare awareness framework have also aided the growth of the global market. Subsidization of vaccinations and mandates from global healthcare bodies have also benefitted the global market for meningococcal diseases.

Global meningococcal market is anticipated to mask a CAGR of 11.5% during the forecast period i.e. 2019-2027. North America is projected to be a highly lucrative market for meningococcal vaccines during the forecast period. The region held major share of the global meningococcal vaccines market due to high rate of adoption of advanced products and rise in penetration of new entrants with novel technology. The U.S. held a major share of the market in North America as well as globally. The country is a major innovation hub, where the world’s leading companies conduct research and development.

Production of Cheap and Quality Vaccines

Manufacturing quality vaccines at affordable prices, various public private partnerships for carrying out research and development activities and presence of vaccines in pipeline and their expected commercialization such as MenACWY are the key factors driving the growth of meningococcal vaccines market. Furthermore, presence of various government awareness programs, increasing government interventions in refining healthcare infrastructure and incorporation of security guidelines pertaining to meningococcal vaccines are expected to positively reinforce market growth. Growing incidences and mortality rates due to meningococcal diseases have caused the federal government to involve and support R&D initiatives and distribution of meningococcal vaccines. For instance, introduction of MenA Conjugate Vaccination Programe in Africa is expected to prevent 123,000 deaths.

This report also provides the existing competitive scenario of some of the key players of the global meningococcal vaccination market which includes company profiling of Baxter International, Biomed Pvt. Ltd., GlaxoSmithKline Plc, JN-International Medical Corporation, Novartis International, Neuron Biotech, Pfizer Inc., Sanofi S.A. and Serum Institute of India Ltd. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global meningococcal vaccine market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.